TransCode Therapeutics, Inc.
RNAZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8,962 | $6,503 | $2,388 | $23,532 |
| - Cash | $2,835,916 | $7,375 | $11,569 | $5,811 |
| + Debt | $0 | $0 | $0 | $38 |
| Enterprise Value | -$2,826,954 | -$872 | -$9,181 | $17,759 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$5 | -$13 | -$51 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$4,845 | -$4,263 | -$12,034 | -$5,791 |
| % Margin | – | – | – | – |
| Net Income | -$4,856 | -$4,277 | -$12,085 | -$5,916 |
| % Margin | – | – | – | – |
| EPS Diluted | -5,824.82 | -5.13 | -70.28 | -16.61 |
| % Growth | -113,444.2% | 92.7% | -323.1% | – |
| Operating Cash Flow | -$4,083 | -$4,194 | -$3,097 | -$3,146 |
| Capital Expenditures | $0 | -$0 | $0 | -$1 |
| Free Cash Flow | -$4,083 | -$4,194 | -$3,097 | -$3,147 |